SHORT COMMUNICATION

In Vitro Activity of Etanidazole against the Protozoan Parasite
Trypanosoma cruzi
Chagas disease is widespreading throughout Latin America where nearly 20 million people are infected by Trypanosoma cruzi and 90 million are at risk in endemic areas (WHO 2000) .
Current treatment for Chagas disease is dependent on the 2-nitroimidazole Benznidazole (Radanil, Roche), the only drug available for human use in Brazil and Argentina. This specific chemotherapy has limitations such as lack of effectiveness to achieve parasitologic cure or prevent the chronic phase of disease and emergence of parasite resistance (Urbina 1999) . Moreover, the therapeutic dose is very close to the toxic dose, which turns this drug poorly tolerated, and severe side effects have been reported (Cançado 2002) . In spite of this, the WHO (1999) has indicated that every T. cruzi-infected individual should be subjected to parasiticidal chemotherapy, independently from the stage of infection they undergo. It is worth to remark the lack of interest shown by pharmaceutical companies in protozoal infections given the high cost of drug development and limited -in value -market for these antiprotozoan drugs. In this context, there is a con- (Coleman et al. 1984) , which was proven to be less toxic in vivo compared to other evaluated 2-nitroimidazoles (Hurwitz et al. 1992) .
EZL [N-(2-hydroxyethyl)-2-nitro-1-imidazoleacetamide] was obtained from NIH (US) and BZL (N-benzyl-2-nitro-1-imidazoleacetamide) was provided by Roche Laboratories (Buenos Aires, Argentina) and was used as reference drug in every assay (Fig. 1 ). Stock solution of EZL was prepared in 10 mM TRIS, 0.85% ClNa, pH 7.4. BZL was solubilized in DMSO and the stock solution was prepared in 10 mM TRIS, 0.85% ClNa, pH 7.4. The final DMSO concentration in the experiments never exceeded 0.1% (vol/vol) and had no deleterious effect by itself on parasites or host cells.
T. cruzi trypomastigotes, RA strain, were grown and purified from monolayers of Vero cells cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum, 100 UI/ml penicillin and 100 µg/ml streptomycin (RPMI-10%).
To evaluate the anti-trypomastigote activity, trypomastigotes (10 6 /ml) were incubated in RPMI-10% at 37ºC in the presence or absence of EZL (14.8 to 1200 µM) or BZL (1.48 to 120 µM). After 24 or 48 h-culture, reduction in T. cruzi number (parasite lysis) was determined using a Neubauer chamber. The LD 50 value (drug concentration that resulted in a 50% reduction compared to the untreated control) was estimated by plotting percentage of reduction against the logarithm of drug concentration. Assays of anti-amastigote activity were performed in Vero cells or J774 murine macrophages. Cells were seeded at a density of 50,000 cells/well in 24-well microplates with rounded coverslips on the bottom. After infection at a parasite-to-cell ratio of 10:1 for 24 h at 37°C, extracellular parasites were removed by six washes with PBS, pH 7.2, and fresh medium containing EZL (3 to 243 µM), BZL (0.3 to 24.3 µM) or none was added. Seventy two hours later, the coverslips were fixed and stained with Giemsa and the number of amastigotes/100 cells was calculated by use of light microscopy. Anti-amastigote activity was expressed as: % AA = [1-(nr amast/100 cells) treated/ (nr amast/100 cells)control] x 100. The IC 50 was defined as the drug concentration required to achieve 50% inhibition of intracellular amastigote growth.
Cytotoxicity assays were carried out on Vero cells or J774 murine macrophages seeded in 96-well flat bottom microplates (10 5 cells/well) in 200 µl of RPMI-10%. The cells were allowed to attach for 24 h at 37ºC and then exposed to EZL (3 to 243 µM) or BZL (0.3 to 24.3 µM) for 72 h. After incubation, the cells were washed with PBS and incubated with sodium 3'-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis-(4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) 200 µg/ml for 4 h. XTT solution was removed and the extent of reduction of XTT to formazan within the cells was quantified by measurement of spectrophotometrical absorbance at 450 nm using an ELISA reader (Meletiades et al. 2001) . Each concentration was assayed three times and six cell growth controls were used for each test.
As shown in Fig. 2a , EZL treatment provoked a dosedependent reduction in the number of RA trypomastigotes of T. cruzi, with the most remarkable effect achieved at 48 h. EZL was again notably active against the clinically relevant intracellular amastigote forms of T. cruzi. Indeed, amastigotes infecting Vero cells or J774 macrophages were more susceptible to the new compound than trypomastigotes (Fig. 2b) . At the observation timepoint after infection (72 h), only intracellular forms of the parasite could be seen in drug-treated cell cultures. No change in the viability of Vero cells or J774 macrophages could be observed even at the highest concentration of the drugs tested, indicating that T. cruzi and not host cells is the target for EZL (Fig. 2b, d ).
Our results (Fig. 2c, d J774 macrophages) for amastigotes] is less potent than BZL [LD 50 values from 6.6 µM (24 h) to 2.2 µM (48 h) for trypomastigotes and IC 50 values from 1.7 µM (Vero) to 1µM (J774) for amastigotes] in eliminating parasites. It is likely that prolonged in vivo administration of EZL should be required to achieve a trypanocidal activity equivalent to that exhibited by BZL. Nevertheless, this may not be a disadvantage for the clinical application of this compound taking into account that, compared to other evaluated 2-nitroimidazoles, EZL has demonstrated to be less neurotoxic in vivo (Coleman et al. 1984) . Undesired toxic side effects have always been considered a serious drawback for BZL chemotherapy in Chagas patients (Cançado 2002) .
In this study, EZL was effective in vitro against the highly virulent RA strain of T. cruzi. However, its parasiticidal action should also be examined against other strains of the parasite, at the light of reported failures of chemotherapy in eliminating some T. cruzi isolates (Filardi & Brener 1987) .
Although the mechanism of trypanocidal action of EZL remains to be elucidated, previous studies have indicated that under normal oxygen tension EZL experiences a futile redox cycling that generates reactive oxygen species (ROS) toxic for the parasites. However, under hypoxic conditions, EZL is reduced by oxygen-sensitive nitroreductases to free radical species which form adducts with a series of macromolecules. On the other hand, under normal oxygen tension BZL seems to be reduced by putative oxygen-insensitive nitroreductases, and many works have found its reduction products covalently bound both to host and parasite moieties, whereas there is no generation of ROS nor futile redox cycling experienced (Lord et al. 1993) . Hence, it is expected that both 2-nitroimidazoles metabolize and exert their parasiticidal action by different pathways.
In conclusion, we have found out a completely novel and different application for EZL, demonstrating that this 2-nitroimidazole displays a defined anti-T. cruzi activity against both circulating and intracellular stages of the parasite. Though EZL presented higher LD 50 and IC 50 than those corresponding to BZL, the reference drug for treatment of chagasic patients, its known lack of significant toxicity in human antitumor therapy (Coleman et al. 1984 , Wasserman et al. 1991 , Riese et al. 1994 , Marcus et al. 2003 supports further investigations, including in vivo evaluation, to establish the real potential of this compound as chemotherapeutic agent against Chagas disease.
